论文部分内容阅读
目的建立裸鼠前列腺癌骨转移模型,探讨塞来昔布作为血管抑制剂对前列腺癌骨转移的形成及生长的影响。方法将30只前列腺癌骨转移裸鼠随机分成二组,第一组隔日予以生理盐水,腹腔注射;第二组隔日予以塞来昔布30 mg/kg,腹腔注射;30 d后处死。检测血清碱性磷酸酶,采用免疫组化和图象分析系统测定血管内皮生长因子(VEGF)和肿瘤微血管密度(MVD),光镜下观察各组肿瘤组织,流式细胞仪检测肿瘤细胞的凋亡。结果治疗组肿瘤的生长明显受到抑制(P<0.01),塞来昔布组肿瘤组织中的VEGF和MVD与对照组比较无统计学意义(P<0.01),抑瘤率为54.47%,凋亡指数由(4.68±1.83)%上升到(24.93±6.14)%,血清碱性磷酸酶由(26.5±4.93)U/L下降到(17.17±3.13)U/L。结论塞来昔布能显著抑制裸鼠前列腺癌骨转移瘤的生长和新生血管形成。
OBJECTIVE: To establish a bone metastasis model of prostate cancer in nude mice and to investigate the effect of celecoxib as an angiostatic agent on the formation and growth of bone metastasis of prostate cancer. Methods Thirty prostate cancer patients with bone metastasis were randomly divided into two groups. The first group received normal saline and injected intraperitoneally every other day. The second group received celecoxib 30 mg / kg on the next day and injected intraperitoneally. After 30 days, they were sacrificed. Serum Alkaline phosphatase was detected. VEGF and MVD were detected by immunohistochemistry and image analysis system. The tumor tissues were observed under light microscope. Death. Results The growth of tumor in the treatment group was significantly inhibited (P <0.01). The VEGF and MVD in the celecoxib group were not significantly different from those in the control group (P <0.01), and the tumor inhibition rate was 54.47% The index increased from (4.68 ± 1.83)% to (24.93 ± 6.14)% and the serum alkaline phosphatase decreased from (26.5 ± 4.93) U / L to (17.17 ± 3.13) U / L. Conclusion Celecoxib can significantly inhibit the growth and neovascularization of bone metastases of prostate cancer in nude mice.